Literature DB >> 2870800

Effect of diethyldithiocarbamate on cis-diamminedichloroplatinum(II)-induced cytotoxicity, DNA cross-linking, and gamma-glutamyl transpeptidase inhibition.

D L Bodenner, P C Dedon, P C Keng, R F Borch.   

Abstract

Diethyldithiocarbamate (DDTC) has been shown to protect against the toxicity of cis-diamminedichloroplatinum(II) (DDP) without inhibition of antitumor effect. We report here that DDTC is unreactive toward DDP complexes in which both chlorides have been replaced by guanine residues but removes platinum from a variety of other ligands, and that this difference in reactivity may provide the basis for the selective protection observed with DDTC. Platinum-DNA complexes were unreactive toward DDTC (10 mM, greater than 4 h) when the platinum:base ratio r less than 0.02. DDTC did not react with the 1:2 complex of DDP:guanosine but reacted rapidly with the 1:1 complex and with the 1:2 complexes of DDP:adenosine. Reaction of DDP with DDTC was second order with a rate constant k = 4.4 M-1 min-1 at 37 degrees C, corresponding to a t 1/2 = 150 min at [DDTC] = 1 mM. Treatment of L1210 cells with DDTC (0.5-1 mM) after exposure to DDP indicated that DDTC had no effect on cell kill if DDTC treatment was delayed for 1 h after DDP. The effect of DDTC on DDP-induced DNA interstrand cross-links was also examined in L1210 cells. Interstrand cross-links were decreased by approximately 50% when cells were treated with DDTC immediately after DDP; no change in DNA interstrand cross-links was observed when DDTC treatment occurred 3 h after DDP. A modified alkaline elution procedure was used to evaluate the effects of high concentrations of DDTC, thiourea, and cyanide on platinum:DNA cross-links from L1210 DNA. Exposure to DDTC (0.5 M, 4 h) did not alter interstrand cross-links, but both thiourea and cyanide caused extensive reversal of cross-links at concentrations as low as 10 and 1 mM, respectively. Both commercial and rat kidney brush border preparations of gamma-glutamyl transpeptidase were inhibited by exposure to 2 mM DDP; exposure of the inhibited enzyme to DDTC (1 or 10 mM) resulted in significant restoration of enzyme activity. These data indicate that DDTC has unique chemical specificity in its reactions with platinum complexes and that this specificity is ideal for application as a chemoprotective drug against cis-platinum toxicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2870800

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Discrepancy between cytotoxicity and DNA interstrand crosslinking of carboplatin and cisplatin in vivo.

Authors:  W DeNeve; F Valeriote; E Tapazoglou; C Everett; A Khatana; T Corbett
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

2.  Novel palladium(II) complexes containing a sulfur ligand: structure and biological activity on HeLa cells.

Authors:  EnJun Gao; Feng Guan; XiaNan Gao; MingChang Zhu; Lei Liu; ChuanSheng Wang; WanZhong Zhang; YaGuang Sun
Journal:  J Biol Inorg Chem       Date:  2011-10-11       Impact factor: 3.358

3.  Modification of the tandem reactive centres of human inter-alpha-trypsin inhibitor with butanedione and cis-dichlorodiammineplatinum(II).

Authors:  M W Swaim; S V Pizzo
Journal:  Biochem J       Date:  1988-08-15       Impact factor: 3.857

4.  A density functional reactivity theory (DFRT) based approach to understand the interaction of cisplatin analogues with protecting agents.

Authors:  Amrit Sarmah; Ram Kinkar Roy
Journal:  J Comput Aided Mol Des       Date:  2014-09-03       Impact factor: 3.686

5.  Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells.

Authors:  Daniela Buac; Sara Schmitt; George Ventro; Fathima Rani Kona; Q Ping Dou
Journal:  Mini Rev Med Chem       Date:  2012-10       Impact factor: 3.862

6.  Reaction kinetics of cisplatin and its monoaquated species with the (potential) renal protecting agents (di)mesna and thiosulfate. Estimation of the effect of protecting agents on the plasma and peritoneal AUCs of CDDP.

Authors:  O R Leeuwenkamp; W J van der Vijgh; J P Neijt; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  [Pt(O,O'-acac)(γ-acac)(DMS)]: Alternative Strategies to Overcome Cisplatin-Induced Side Effects and Resistance in T98G Glioma Cells.

Authors:  Valentina Astesana; Pawan Faris; Beatrice Ferrari; Stella Siciliani; Dmitry Lim; Marco Biggiogera; Sandra Angelica De Pascali; Francesco Paolo Fanizzi; Elisa Roda; Francesco Moccia; Maria Grazia Bottone
Journal:  Cell Mol Neurobiol       Date:  2020-05-19       Impact factor: 5.046

8.  High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations.

Authors:  M W DeGregorio; D R Gandara; W M Holleran; E A Perez; C C King; H G Wold; T J Montine; R F Borch
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  Treatment of DNA with ammonium bicarbonate or thiourea can lead to underestimation of platinum-DNA monoadducts.

Authors:  G R Gibbons; J D Page; S G Chaney
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP).

Authors:  J Kralovánszky; N Prajda; S Kerpel-Fronius; F Gál; F Kiss
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.